PD-1, a receptor primarily expressed on activated CD8+ T cells, is responsible for downregulating tumour-specific T-cell responses.18 Adverse effects of anti-PD-1 mAbs can occur in the endocrine system, lungs, liver, and gastrointestinal tract. This evidence concerns the gene CD8A and neoplasm.